PicoCELA Inc. (NASDAQ:PCLA) Sees Significant Drop in Short Interest

PicoCELA Inc. (NASDAQ:PCLA) saw a large drop in short interest in the month of January. As of January 15th, there was short interest totaling 1,932,063 shares, a drop of 46.7% from the December 31st total of 3,625,291 shares. Based on an average trading volume of 4,234,824 shares, the short-interest ratio is currently 0.5 days. Approximately 212.3% of the shares of the company are sold short. Approximately 212.3% of the shares of the company are sold short. Based on an average trading volume of 4,234,824 shares, the short-interest ratio is currently 0.5 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PicoCELA in a research report on Friday, January 9th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, PicoCELA presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. XTX Topco Ltd acquired a new position in shares of PicoCELA Inc. (NASDAQ:PCLA) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned about 0.16% of PicoCELA as of its most recent SEC filing.

PicoCELA Price Performance

Shares of PicoCELA stock traded up $0.56 on Friday, hitting $6.33. The company’s stock had a trading volume of 45,830 shares, compared to its average volume of 103,227. PicoCELA has a 52-week low of $3.46 and a 52-week high of $294.00. The firm has a fifty day moving average price of $7.59 and a 200-day moving average price of $11.58.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.